Do GLP-1 Weight Loss and Diabetes Drugs Increase the Risk…

Do GLP-1 Weight Loss and Diabetes Drugs Increase the Risk of Vision Loss? New Study Offers Important Perspective Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including medications used to treat type 2 diabetes and obesity, have transformed metabolic care in recent years. However, questions have emerged about whether these drugs may be associated with a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), a leading cause of sudden optic nerve–related vision loss in older adults. A new nationwide cohort study published in the Annals of Internal Medicine examined this potential association using health data from more than 293,000 adults with type 2 diabetes in Sweden. Researchers compared people who started GLP-1 receptor agonists with those who initiated SGLT-2 inhibitors, another